Guidelines for the Diagnosis and Management of Paroxysmal Nocturnal Hemoglobinuria (PNH) at Hospital Universitário Walter Cantídio.

Authors

  • Rafaela Pitombeira Universidade Federal do Ceará
  • Fernando Barroso Duarte Universidade Federal do Ceará

DOI:

https://doi.org/10.46765/2675-374X.2025v6n1p256

Abstract

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and poorly understood clonal disease in our region. It is caused by somatic mutations in the PIGA gene on the X chromosome. Such mutations result in the absence of GPI production, which is an anchoring structure for proteins like CD55 and CD59 that protect red blood cells from lysis mediated by the complement system. PNH presents a diverse clinical course that includes intravascular hemolysis, thrombosis, and cytopenias. Following the advent of the humanized monoclonal antibody Eculizumab, which inhibits the C5 portion of the complement system, thereby preventing the destruction of red blood cells by the membrane attack complex, there has been a significant change in the treatment of PNH and in the lives of its patients. This study aims to present the guidelines for the diagnosis and management of patients with PNH followed at a reference public hospital in Ceará, Brazil.

Downloads

Published

07/01/2025

How to Cite

Pitombeira, R., & Duarte, F. (2025). Guidelines for the Diagnosis and Management of Paroxysmal Nocturnal Hemoglobinuria (PNH) at Hospital Universitário Walter Cantídio. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 6(1), 256. https://doi.org/10.46765/2675-374X.2025v6n1p256

Issue

Vol. 6 No. 1 (2025): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Protocols of conduct

License

Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Most read articles by the same author(s)